ArticleBMC public health2026
Interferon gamma release assay and sputum GeneXpert positivity for tuberculosis burden detection in people deprived of liberty in Brazil: a cross-sectional study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundGlobally tuberculosis disease (TB) poses a significant public health challenge. People deprived of liberty (PDL) are one of the most affected. This study aims to evaluate the positivity of interferon gamma release assay (IGRA) and molecular sputum testing for TB through a multicenter survey of Brazilian prisons and evaluate factors associated with IGRA positivity.
methodsWe performed a cross-sectional study among PDL in six male and two female prisons within 6 cities in Brazil in 2025. Eligible participants included consenting adults over 18 years. We randomized 130 individuals per site using prison census for evaluation with a sociodemographic questionnaire, blood testing with QuantiFERON-TB Gold Plus
resultsAmong 1040 PDL randomized, 884 were included. The overall IGRA positivity was 53.6% (95% confidence interval [CI] 50.3-56.9) varying between 29.2% (21.6-38.2) and 84.0% (75.3-90.1) among prisons sites, male and female individuals had a positivity of 61.9% (58.1-65.5) and 30.3% (24.7-36.5), respectively. In the multivariable analysis, IGRA positivity was associated with lower education (adjusted odds ratio [aOR] 1.46, 95% CI 1.03-2.07, p = 0.034), previous incarceration (aOR 2.81, 1.85-4.25, p < 0.001), previous TB history (aOR 2.99, 1.39-6.42, p < 0.001) and incarceration time (< 1 year as reference, 3-4 years: aOR 2.15, 1.18-3.92, p = 0.012; 5 years or above: aOR 2.85, 1.66-4.90, p < 0.001) for males. In females, IGRA positivity was associated with previous TB history (aOR 5.93, 1.97-20.2, p = 0.002). One prison could not collect sputum samples; at the remaining sites we detected 20 individuals (2.5%, 20/770) with positive Xpert.
conclusionDespite variations among prisons and gender, IGRA and Xpert positivity were elevated across sites evaluated in Brazil. These findings underscore the urgent need for systematic and comprehensive tuberculosis screening, prevention, and control strategies in prisons, including the potential evaluation of new preventative technologies such as new TB vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.